Quarterly ResultSep 17, 2026, 01:34 PM
VitaSpring Biomedical Reports Q2 Net Loss of $155,817; Management Transition
AI Summary
VitaSpring Biomedical Co., Ltd. filed its 10-Q report for the period ending July 31, 2026. The company reported a net loss of $155,817 for the three-month period and $231,661 for the six-month period. Total assets stood at $14,822, while total liabilities reached $4,677,051, resulting in a significant accumulated deficit of $5,928,532. The company's cash balance was minimal at $13,367. A significant management and board transition occurred on September 7, 2026, with new leadership appointed. The company continues to face going concern issues due to its financial condition.
Key Highlights
- VitaSpring Biomedical Co., Ltd. reported a net loss of $155,817 for the three months ended July 31, 2026.
- The company reported a net loss of $231,661 for the six months ended July 31, 2026.
- Total assets were $14,822 as of July 31, 2026, compared to $14,676 as of January 31, 2026.
- Total liabilities were $4,677,051 as of July 31, 2026, compared to $4,445,244 as of January 31, 2026.
- The company has an accumulated deficit of $5,928,532 as of July 31, 2026.
- Cash balance was $13,367 as of July 31, 2026.
- Management transition occurred on September 7, 2026, with new appointments for Chairman of the Board, CEO, President, CFO, and Secretary.
Price Impact